The color of unmatched intranasal protection.
NEW Bovilis NASALGEN® 3-PMH is the first and only intranasal BRD vaccine offering protection against IBR, BRSV, PI3, Pasteurella multocida and Mannheimia haemolytica. Safe to use in young calves for a strong, healthy foundation. And a unique BluShadowTM diluent means there’s no second guessing which animals have been vaccinated.
Designed for no injection site reactions to help your operation meet Beef Quality Assurance standards.
Key Benefits
- Designed with IBR and PI3 strains that are not temperature-sensitive.1 Ensures the vaccine will replicate and protect in any situation.
- Unique BluShadowTM diluent for confident administration.
- Eliminates the need and stress of two separate vaccines.
- Safe in pregnant cows and in calves nursing pregnant cows.
Powerful, long-lasting duration of immunity2
- At least 195 days against IBR
- At least 95 days against PI3
- At least 78 days against BRSV
- At least 125 days against P. multocida
- At least 122 days against M. haemolytica
Dosing and Usage
- Convenient, single 2 mL dose in one nostril
- Mimics natural exposure to the most common causes of pneumonia for an effective immune response
- SUPPLIED: 1-dose, 10-dose, 50-dose
Research
Efficacy of the Pasteurella multocida Fraction of Nasalgen® 3-PMH in Calves 1 to 4 Days Old
Results of this study demonstrate protective efficacy of the Pasteurella multocida fraction of NASALGEN® 3-PMH.
Duration of Immunity of the Pasteurella multocida Fraction of Nasalgen® 3-PMH Administered to Calves at 2 to 3 Days of Age
Results of this study demonstrate the duration of immunity of the Pasteurella multocida fraction of NASALGEN® 3-PMH.
Efficacy of the Mannheimia haemolytica Fraction of Nasalgen® 3-PMH in Calves 2 to 4 Days Old
Results of this study demonstrate protective efficacy of the Mannheimia haemolytica fraction of NASALGEN® 3-PMH.
Duration of Immunity of the Mannheimia haemolytica Fraction of Nasalgen® 3-PMH Administered to Calves 4 to 6 Days of Age
Results of this study demonstrate the duration of immunity of the Mannheimia haemolytica fraction of NASALGEN® 3-PMH.
Efficacy of the Bovine Respiratory Syncytial Virus Fraction of Nasalgen® 3-PMH in Calves 4 to 7 Days Old
Significant differences in lung lesion scores and viral shedding between Nasalgen 3-PMHvaccinated and control groups confirmed the immunogenic efficacy of the BRSV fraction of N3PMH.
Duration of Immunity of the Bovine Respiratory Syncytial Virus Fraction of Nasalgen® 3-PMH Administered to Calves 5 to 7 Days of Age
This study reaffirms the safety and efficacy of N3PMH and establishes the duration of immunity of the BRSV fraction of N3PMH to be at least 78 days following one dose of vaccine administered intranasally to calves 5 to 7 days of age.
Efficacy of the Infectious Bovine Rhinotracheitis Fraction of Nasalgen® 3-PMH in Calves 4 to 7 Days Old
Results of this study demonstrate protective efficacy for the IBR viral fraction of Nasalgen 3-PMH and no interference by the other four antigens in N3PMH after one intranasal administration to calves 4 to 7 days old.
Duration of Immunity of the Infectious Bovine Rhinotracheitis Virus Fraction of Nasalgen® 3-PMH Administered to Calves 3 to 5 Days of Age
This study reaffirms the safety and efficacy of N3PMH and establishes the duration of immunity of the IBR fraction of N3PMH to be at least 195 days following one dose of vaccine administered intranasally to calves 3 to 5 days of age.
Efficacy of the Bovine Parainfluenza 3 Virus Fraction of Nasalgen® 3-PMH in Calves 6 or 7 Days Old
Results of this study demonstrate protective efficacy of the PI3 fraction of Nasalgen 3-PMH and confirmed the non-interference by the other antigenic fractions in N3PMH when administered intranasally to healthy calves 6 or 7 days old.
Duration of Immunity of the Parainfluenza 3 Fraction of Nasalgen® 3-PMH Administered to Calves 3 to 5 Days of Age
This study reaffirms the safety and efficacy of N3PMH and establishes the duration of immunity of the PI3 fraction of N3PMH to be at least 95 days following one dose of vaccine administered intranasally to calves 3 to 5 days of age.
No items to show.
1 Grissett GP, et al. Effect of Ambient Temperature on Viral Replication and Serum Antibody Titers Following Administration of a Commercial Intranasal Modified-Live Infectious Bovine Rhinotracheitis-Parainfluenza-3 Virus Vaccine to Beef Cattle Housed in High- and Moderate-Ambient Temperature Environments. Am J Vet Res. 2014;75(12):1076-1082.
2Data on file at Merck Animal Health and USDA.